Gonorrhea is prevented through a combination of barrier methods during sex, regular screening, prompt treatment of infections, and newer strategies like post-exposure antibiotics. No single method is foolproof, but layering several approaches significantly lowers your risk of getting or spreading the infection.
Condoms and Barrier Methods
Consistent, correct use of external (male) condoms during vaginal, anal, and oral sex is the most accessible way to reduce gonorrhea transmission. Internal (female) condoms offer similar protection. Dental dams lower risk during oral sex. The key word is “consistent.” Using a condom most of the time still leaves gaps, and gonorrhea spreads easily through direct contact with infected mucous membranes in the throat, rectum, urethra, and cervix.
Barrier methods work best when used from start to finish of sexual contact, not just during ejaculation. Gonorrhea transmits through pre-ejaculatory fluid and mucosal contact alone, so even brief unprotected contact carries risk. Water-based or silicone-based lubricants help prevent condom breakage, which is one of the more common reasons barrier protection fails in practice.
Screening at the Right Intervals
Regular testing catches infections you wouldn’t know about otherwise. Gonorrhea is frequently asymptomatic, especially in the throat and rectum, so many people unknowingly pass it to partners. Getting screened on a schedule based on your risk level is one of the most effective prevention tools available.
CDC guidelines recommend annual gonorrhea screening for sexually active women under 25 and for women 25 and older who have risk factors like a new partner, multiple partners, a partner with concurrent partners, or inconsistent condom use. Men who have sex with men should be screened at least once a year at all sites of contact (urethra, rectum, and throat) regardless of condom use, and every 3 to 6 months if at higher risk. After a positive test and treatment, retesting 3 months later is recommended to catch reinfection.
The standard test is a nucleic acid amplification test, which can be done on a urine sample or a swab from the vagina, rectum, or throat. If you’ve had a new exposure, the test reliably detects gonorrhea about one week after contact and catches nearly all infections by two weeks. Testing earlier than that may miss a new infection.
Treating Partners to Break the Chain
One of the biggest drivers of ongoing gonorrhea transmission is reinfection from an untreated partner. You get treated, have sex with the same partner who hasn’t been tested or treated, and the cycle starts again. Partner notification and treatment is a critical, often overlooked, piece of prevention.
Expedited partner therapy lets a healthcare provider prescribe or provide medication for a patient’s sexual partner without requiring that partner to come in for a separate visit. Evidence shows this approach reduces reinfection rates compared to simply telling your partner to go get tested on their own. The benefits of preventing reinfection outweigh the small risks of providing antibiotics to someone who hasn’t been examined in person. Expedited partner therapy is legal in most U.S. states, though rules vary.
Doxycycline After Exposure (Doxy-PEP)
A newer prevention strategy involves taking an antibiotic called doxycycline after a potential exposure. In 2024, the CDC issued guidelines recommending that providers discuss this option with gay, bisexual, and other men who have sex with men and with transgender women who have had at least one bacterial sexually transmitted infection (gonorrhea, chlamydia, or syphilis) in the past 12 months.
The approach works like this: you take a single 200 mg dose of doxycycline as soon as possible within 72 hours after having oral, vaginal, or anal sex, with a maximum of one dose per 24-hour period. Clinical trials showed strong effectiveness against chlamydia and syphilis, though its effectiveness against gonorrhea specifically has been less consistent. This is partly because antibiotic-resistant gonorrhea strains are increasingly common. Doxy-PEP is not currently recommended for cisgender women, as the available trial data did not show the same benefit in that group.
This strategy is meant for people at high, ongoing risk. It is not a replacement for condoms or regular screening but an additional layer of protection.
A Vaccine on the Horizon
There is no vaccine specifically designed for gonorrhea, but a meningococcal B vaccine (originally developed to prevent bacterial meningitis) has shown cross-protection against gonorrhea. The bacteria that cause meningitis and gonorrhea are closely related, and certain proteins targeted by the vaccine overlap between the two organisms.
Observational studies have found that the vaccine reduces gonorrhea infections by roughly 35% to 59% for up to three years after vaccination. The strongest results came from younger recipients: among 18- to 19-year-olds who received two doses, effectiveness reached 59%. A large U.S. study found 40% effectiveness with a complete vaccination series. Protection appears to decline somewhat after 36 months, dropping from about 35% in the first three years to around 23% beyond that point.
These numbers are modest compared to vaccines for diseases like measles or HPV, but for a sexually transmitted infection with no dedicated vaccine and growing antibiotic resistance, even partial protection at a population level could meaningfully slow transmission. Research into a purpose-built gonorrhea vaccine continues.
Reducing Risk in Practical Terms
Prevention works best as a set of overlapping habits rather than reliance on any single strategy. In practice, that looks like using condoms consistently, getting screened on a schedule that matches your sexual activity, making sure partners are tested and treated after a diagnosis, and discussing options like doxy-PEP with a provider if you’re at higher risk.
Mutual monogamy with a partner who has tested negative is also effective, though it requires both partners to actually get tested rather than assume they’re infection-free. Reducing the number of sexual partners lowers your statistical exposure, but gonorrhea can transmit in a single encounter, so partner count alone isn’t a reliable gauge of safety.
Throat and rectal infections deserve special attention because they rarely produce symptoms and are easily missed without site-specific testing. If you have oral or anal sex, let your provider know so they can test the right sites. A urine test alone will not detect gonorrhea in the throat or rectum.